

These recommendations along with other recommendations of the Committee and other proposals for electoral reforms are under the examination of the Government.

**Economics of Diesel vis-a-vis Electric Railway Engines.**

\*1043. SHRI BALWANT SINGH RAMOOWALIA: Will the Minister of RAILWAYS be pleased to state:

(a) whether he has received the report of Economic studies on Diesel vis-a-vis Electric Railway engines;

(b) is it correct that this report was to be submitted by 15th March, 1978;

(c) if the report has come, what are the recommendations; and

(d) if not, why it has been delayed and when is it expected?

THE MINISTER OF RAILWAYS (PROF. MADHU DANDAVATE): (a) No, Sir.

(b) to (d). The report of the Committee on economics on diesel and electric tractions on Indian Railways was originally scheduled to be finalised by 15th February, 1978. This could not be done as collection of large volume of data involving enormous amount of work is taking time. The report is expected to be finalised very shortly.

**Memorandum from Employees Unions of Glaxo Laboratories**

\*1044. SHRI BHAGAT RAM: Will the Minister of PETROLEUM, CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether any memorandum has been received by the Government regarding malpractices being indulged in the Glaxo Laboratories India Limited, Bombay, submitted by Central Committee of Glaxo Employees Unions in India in the month of May, 1977;

(b) what were the allegations against the management of the said company;

(c) whether any enquiry has been made into the allegations contained in the memorandum and what are the findings and Government's reaction thereto; and

(d) if not, the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF PETROLEUM AND CHEMICALS AND FERTILIZERS (SHRI JANESHWAR MISHRA): (a) to (d). Yes, Sir. A Statement furnishing the allegations contained in the Memorandum is attached. The allegations are being examined in consultation with the State Drug Controllers, BICP, Ministry of Labour and the Company.

**Statement**

1. Adoption of unfair methods to get substantial price increases for its products.

2. Avoidance of price reduction consequent to cost reduction by keeping vital information concealed from Government.

3. Increase in price of food products even where costs have not increased or where ingredient costs have come down.

4. Lavish spending by the company to hoodwink the Government in regard to provisions of Drug (Price Control) Order, 1970.

5. Discontinuation or under production of essential drugs solely for reasons that they are less profitable.

6. Producing and increasing sales of highly profitable and scheduled drugs through questionable and un-ethical means.

7. Unethical practice of supply of huge quantities of samples in original packs to doctors; expensive gifts to Medical professions and lavish entertainment.

8. Adoption of questionable methods in purchase and import of raw materials and machinery and routing the same through the Parent company in U.K.

9. Taking recourse to buying political favour.